Your privacy is very important for us. When you visit our website, please agree to use all cookies. For more information about how we use cookies, please visit our Privacy Policy.

中

News Center

6756758(2)-91.jpg

LaNova Medicines Completes USD 42 Million Series C1 Financing to Accelerate Clinical Progress and Innovation Platform Development

Learn More

All

2025

2024

2023

2022

2021

2020

LaNova Medicines and Junshi Biosciences Enter into Multiple Combo Clinical Collaborations

2021-10-23

Learn More
LaNova Medicines and CBMG Enter into A Strategic Partnership

2021-10-22

Learn More
LaNova Medicines' LM-302 receives NMPA IND Approval

2021-10-15

Learn More
LaNova Medicines Holds Townhall Meeting to Celebrate 2nd Company Anniversary

2021-10-02

Learn More
LaNova Medicines Moved to Its New Office at 999 Cailun Road in Zhangjiang Science Park

On August 2nd, 2021, LaNova Medicines moved to its brand-new office at 999 Cailun Road on Jinke Road in Zhangjiang Science Park, with expanded laboratory and office space. More than 40 employees gathered together in the hall of the new office, and the fou

2021-08-03

Learn More
LM-102 Obtained China NMPA Clinical Trial Approval

LM-102 received China NMPA approval for its China phase I/II clinical study.

2021-06-23

Learn More

6